Health Economics›Diffuse large B-cell lymphoma›Untreated

Untreated

Diffuse large B-cell lymphoma · 51 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
VR-CHOP Variant #01	—	R 30 327	21d	—	—	~6	~R 181 963 indirect	—
R-CHMP Variant #01 Partial	—	R 26 620	21d	—	—	~6	~R 159 718 indirect	—
CCOP Variant #01	—	R 12 372	21d	—	—	~8	~R 98 980 indirect	—
VNCOP-B Variant #01 Partial	—	R 8 501	28d	—	—	~2	~R 16 935 indirect	—
PMitCEBO Variant #01 Partial	—	R 7 229	14d	—	—	~8	~R 57 573 indirect	—
DICEP Variant #01	—	R 6 506	—	—	—	~1	~R 6 506 indirect	—
ACVBP N/A - intrathecal component Partial	—	R 6 243	21d	—	—	4	R 23 852 PFS proxy	1
PEN Variant #01	—	R 5 837	28d	—	—	~2	~R 11 673 indirect	—
ACOMLA Variant #01	—	R 4 431	90d	—	—	~3	~R 13 293 indirect	—
CHOP Modified Variant #01	—	R 4 296	63d	—	—	~1	~R 4 296 indirect	—
CNOP Variant #01	—	R 4 203	28d	—	—	~8	~R 33 625 indirect	—
CNOP (Prednisolone) Variant #01	—	R 3 995	21d	—	—	~6	~R 23 970 indirect	—
P/DOCE Variant #01	—	R 3 170	21d	—	—	~3	~R 4 914 indirect	—
ACEP Variant #01	—	R 3 158	14d	—	—	~4	~R 10 785 indirect	—
CEEP Variant #01 Partial	—	R 2 633	—	—	—	~2	~R 5 266 indirect	—
CEOP (Prednisolone) Variant #01	—	R 2 333	21d	—	—	~6	~R 13 997 indirect	—
F-MACHOP Variant #01	—	R 2 290	21d	—	—	~6	~R 13 742 indirect	—
MACOP-B Variant #01 Partial	—	R 2 170	28d	—	—	~3	~R 6 345 indirect	—
LD-ACOP-B Variant #01 Partial	—	R 2 138	42d	—	—	~2	~R 4 150 indirect	—
DA-EPOCH Variant #01	—	R 2 134	21d	—	—	~8	~R 17 070 indirect	—
COMP Variant #01 Partial	—	R 2 132	37d	—	—	~1	~R 2 132 indirect	—
CHOEP-14 Variant #01	—	R 2 109	14d	—	—	~6	~R 12 655 indirect	—
CHOEP-21 Variant #01	—	R 2 109	21d	—	—	~6	~R 12 655 indirect	—
CEOP Variant #01	—	R 2 095	21d	—	20.3 mo	2	R 4 189 PFS proxy	—
CHOP-B Variant #01 Partial	—	R 2 086	21d	—	—	~6	~R 8 343 indirect	—
HOP Variant #01	—	R 1 924	21d	—	—	~8	~R 8 575 indirect	—
ProMACE-CytaBOM Variant #01 Partial	—	R 1 909	21d	—	—	~3	~R 5 727 indirect	—
VABE Variant #01 Partial	—	R 1 681	14d	—	—	~6	~R 9 964 indirect	—
Cyclophosphamide monotherapy Variant #01	—	R 1 680	28d	—	~15.8 mo	~1	~R 1 680 PFS proxy · indirect	1
PACEBOM Variant #01 Partial	—	R 1 670	14d	—	—	~6	~R 9 834 indirect	—
ProMACE-MOPP Variant #01 Partial	—	R 1 653	28d	—	—	~8	~R 13 226 indirect	—
ACVBP (Methylprednisolone) Variant #01 Partial	—	R 1 486	15d	—	—	~3	~R 4 458 indirect	—
m-BACOD Variant #02 Partial	—	R 1 320	21d	—	~7.6 mo	~11	~R 14 524 PFS proxy · indirect	2
VCAP Variant #01 Partial	—	R 1 249	21d	—	—	~3	~R 3 748 indirect	—
VEPA Variant #01	—	R 1 238	21d	—	—	~2	~R 2 475 indirect	—
VACOP-B Variant #01 Partial	—	R 1 190	14d	—	—	~6	~R 7 142 indirect	—
CHOP-14 Variant #01	—	R 1 166	14d	—	—	6	R 6 997 PFS proxy	1
COP-Bleo Variant #01 Partial	—	R 1 111	28d	—	—	~2	~R 2 223 indirect	—
CHOP (Prednisolone) Variant #01	—	R 1 048	21d	—	~11.8 mo	~8	~R 8 383 PFS proxy · indirect	1
CHOP-BCG Variant #01 Partial	—	R 1 041	28d	—	—	~8	~R 8 332 indirect	—
CAP-BOP Variant #01 Partial	—	R 1 024	28d	—	—	~9	~R 9 219 indirect	—
C-MOPP Variant #01 Partial	—	R 946	28d	—	—	~4	~R 3 785 indirect	—
CHOP Variant #20	—	R 835	21d	—	—	6	R 5 011 PFS proxy	1
CHVmP-VB Variant #01 Partial	—	R 835	21d	—	—	~8	~R 6 680 indirect	—
ABP Variant #01 Partial	—	R 824	21d	—	—	~7	~R 5 770 indirect	—
CHOP Modified (Prednisolone) Variant #01	—	R 662	21d	—	—	~6	~R 3 973 indirect	—
CVP Variant #01	—	R 613	21d	—	—	~8	~R 4 901 indirect	—
CHVP Variant #01 Partial	—	R 446	28d	—	—	~6	~R 2 678 indirect	—
BCOP Variant #01 Partial	—	R 333	28d	—	—	~6	~R 2 001 indirect	—
m-BNCOD Partial	—	—	—	—	—	—	—	—
ACE Partial	—	—	—	—	—	—	—	—

51 of 51 regimens shown